{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:47:51Z","timestamp":1792277271646,"version":"4.4.0"},"reference-count":12,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T00:00:00Z","timestamp":1697932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2024,1]]},"abstract":"Abstract<\/jats:title>Background<\/jats:title>Sinonasal undifferentiated carcinoma (SNUC) is an exceedingly rare head and neck malignancy. No consensus exists on treatment for metastatic disease.<\/jats:p><\/jats:sec>Case<\/jats:title>A 56\u2010year\u2010old female was diagnosed with SNUC after endorsing sinus congestion, diplopia, and right orbital pain. Initially treated with surgery and radiation, she later developed significant metastatic disease. She demonstrated progression of her hepatic metastases under pembrolizumab therapy. However, the addition of ipilimumab and a COX\u20102 inhibitor resulted in significant improvement in her lesions as well as an ongoing durable response. Her regimen was complicated by immune\u2010related adverse events successfully treated with steroids.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Dual checkpoint inhibition deserves consideration when treating metastatic SNUC, especially after single agent therapy has failed. The positive effect of this treatment may be augmented by IDO1 inhibition.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1915","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T04:39:35Z","timestamp":1698035975000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Durable and dramatic response to checkpoint inhibition combined with COX<\/scp>\u20102 inhibitor celecoxib in a patient with p16+ metastatic sinonasal undifferentiated carcinoma: A case study"],"prefix":"10.1002","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7830-1792","authenticated-orcid":false,"given":"Jonathan Q.","family":"Trinh","sequence":"first","affiliation":[{"name":"Department of Internal Medicine University of Nebraska Medical Center Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassaundra","family":"Acosta","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology City of Hope Goodyear Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Easwar","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine City of Hope Goodyear Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Galamaga","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology City of Hope Goodyear Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Rush University Medical Center Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,22]]},"reference":[{"issue":"2","key":"e_1_2_10_2_1","first-page":"94","article-title":"Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States","volume":"76","author":"Chambers KJ","year":"2015","journal-title":"J Neurol Surg B Skull Base"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1159\/000496496"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0776-4"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00224-3"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26472-9"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/03008916211026971"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0400"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33780"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.6014"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7593"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1701"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T14:37:03Z","timestamp":1706279823000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,22]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/cnr2.1915"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1915","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,22]]},"assertion":[{"value":"2023-05-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1915"}}